Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Biomarkers Market Forecasts Growth from $67.95B (2026) to $112.10B by 2031, Profiling Roche, Abbott, Thermo Fisher & Qiagen

globenewswire.com
ABT Abbott is mentioned for expanding its ARCHITECT and Alinity immunoassay systems for infectious disease testing and chronic condition monitoring, indicating growth in the biomarkers market. TMO Thermo Fisher Scientific is profiled as a key participant in the biomarkers market, suggesting its involvement in the sector's growth. LH LabCorp is listed as a company profiled in the biomarkers market report, indicating its participation in this growing sector. RVTY Revvity is listed as a company profiled in the biomarkers market report, indicating its participation in this growing sector. AGNC Agilent Technologies is listed as a company profiled in the biomarkers market report, indicating its participation in this growing sector. BIO Bio-Rad Laboratories is listed as a company profiled in the biomarkers market report, indicating its participation in this growing sector. ILMN Illumina is listed as a company profiled in the biomarkers market report, indicating its participation in this growing sector. QNRX Quanterix is listed as a company profiled in the biomarkers market report, indicating its participation in this growing sector. MYGN Myriad Genetics is listed as a company profiled in the biomarkers market report, indicating its participation in this growing sector. BIIB Bio-Techne is listed as a company profiled in the biomarkers market report, indicating its participation in this growing sector. ES Eurofins Scientific is listed as a company profiled in the biomarkers market report, indicating its participation in this growing sector. STRL StressMarq Biosciences Inc. is listed as a company profiled in the biomarkers market report, indicating its participation in this growing sector. SSTK Standard BioTools is listed as a company profiled in the biomarkers market report, indicating its participation in this growing sector. CNMD C2N Diagnostics is listed as a company profiled in the biomarkers market report, indicating its participation in this growing sector.

Biomarkers Market Forecasts Growth from $67.95B (2026) to $112.10B by 2031, Profiling Roche, Abbott, Thermo Fisher & Qiagen Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "Biomarkers Market by Offering, Type, Research Area, Technology, Disease, Application - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.

The global biomarkers market is projected to grow from USD 67.95 billion in 2026 to USD 112.10 billion by 2031, registering a compound annual growth rate of 10.5% during the forecast period. Market expansion is being supported by the adoption of precision medicine and companion diagnostics, alongside the integration of artificial intelligence, digital pathology, bioinformatics, genomics, proteomics and multi-omics technologies.

Predictive biomarkers lead the efficacy biomarkers segment

By type, the biomarkers market comprises safety, efficacy and validation biomarkers. Efficacy biomarkers are further segmented into predictive, surrogate, pharmacodynamic and prognostic biomarkers. Predictive biomarkers represented the largest share of the efficacy biomarkers segment in 2024, with their leading position continuing into 2025. Growth is primarily associated with their role in identifying patients most likely to respond to specific therapies, supporting personalized treatment selection, clinical decision-making and improved outcomes.

Predictive biomarker adoption is increasing across oncology, autoimmune diseases and infectious diseases. The expanding number of companion diagnostic approvals is also strengthening market demand. In June 2026, the FDA approved Roche's first companion diagnostic for assessing PTEN protein status in prostate cancer. The VENTANA PTEN assay supports the identification of patients eligible for more targeted treatment decisions.

Immunoassays retain the largest technology share

The biomarkers market is segmented by technology into immunoassays, next-generation sequencing, polymerase chain reaction, mass spectrometry, chromatography and other platforms. Immunoassays held the largest market share in 2025, supported by their specificity and broad applicability across oncology, cardiology, infectious diseases and other clinical areas.

Compatibility with clinical diagnostics and research applications, combined with scalability, automation and high-throughput testing capabilities, continues to support immunoassay adoption. Major market participants are enhancing their platforms to expand diagnostic offerings. Roche provides the Elecsys Anti-p53 immunoassay for cancer diagnostics, while Abbott continues to expand its ARCHITECT and Alinity immunoassay systems for infectious disease testing and chronic condition monitoring.

Asia Pacific is expected to record the fastest regional growth

The report analyzes North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. Asia Pacific is projected to register the highest CAGR from 2026 to 2031. Regional growth is being driven by healthcare infrastructure expansion in China, India and Japan, together with investments in precision medicine, genomic research and diagnostic innovation.

The increasing prevalence of cancer, cardiovascular disorders, metabolic diseases and infectious diseases is accelerating demand for biomarker-based diagnostics and personalized treatment strategies. Additional growth factors include expanding clinical trial activity, greater adoption of companion diagnostics, supportive biotechnology and life sciences initiatives, and rapid implementation of genomics, proteomics and AI-enabled analytics. Strengthening local biopharmaceutical manufacturing and evolving regulatory frameworks are also improving commercialization opportunities, positioning Asia Pacific as an important center for biomarkers market growth and innovation.

Research coverage and market analysis

The research categorizes the global biomarkers market by offering, type, research area, technology, disease indication and end user. It evaluates market drivers, restraints, opportunities and challenges while assessing competitive positioning, market shares, growth strategies and product portfolios. The report also reviews business profiles, solutions, approvals, product launches, collaborations, partnerships, agreements, acquisitions, investments, funding activity, vendor valuations, financial metrics and other recent industry developments.

Key growth drivers include the rising adoption of precision medicine and companion diagnostics; greater use of NGS, PCR, proteomics and multi-omics platforms; increasing application of biomarkers in drug discovery and clinical trial design; and the growing burden of cancer, cardiovascular, neurological and infectious diseases. Expansion of liquid biopsy and minimally invasive biomarker testing, together with AI, digital pathology and bioinformatics integration, is also supporting market development.

Market restraints include the high cost of advanced biomarker discovery and validation, as well as complex regulatory and reimbursement pathways. Opportunities include the co-development of biomarkers with targeted therapies and immunotherapies, expansion of blood-based biomarkers for oncology and neurology, advances in proteomics and spatial biology, and increasing outsourcing of biomarker assay development and validation. Principal challenges include translating discovery biomarkers into clinically validated tests and addressing patient heterogeneity and disease complexity.

The report provides detailed insights into research and development pipelines, emerging technologies, high-growth markets, untapped geographies and investment trends. It is designed to help established companies and new entrants evaluate revenue opportunities, understand the competitive environment, strengthen market positioning and develop effective go-to-market strategies.

Primary research respondent profile

Companies profiled in the biomarkers market report

Companies covered include F. Hoffmann-La Roche Ltd. (Switzerland), Merck KGaA (Germany), Abbott (US), Thermo Fisher Scientific, Inc. (US), QIAGEN (Germany), Charles River Laboratories (US), Eurofins Scientific (Luxembourg), LabCorp (US), Revvity (US), bioMerieux (France), Guardant Health (US), JSR Corporation/Crown Biosciences (Japan), Agilent Technologies, Inc. (US), Bio-Rad Laboratories (US), Illumina, Inc. (US), Quanterix (US), Meso Scale Diagnostics, LLC (US), Intertek Group Plc (UK), Meridian Bioscience (US), BioAgilytix Labs (US), R-Biopharm AG (Germany), Enzo Biochem (US), WuXi AppTec (China), Standard BioTools (US), Diatech Pharmacogenetics (Italy), Synexa Life Sciences BV (Netherlands), Proteome Sciences (UK), Pillar Biosciences (US), StressMarq Biosciences Inc. (Canada), Sebia (France), Bio-Techne (US), C2N Diagnostics (US), NorthEast Bioanalytical Laboratories (US), Signosis (US) and Myriad Genetics, Inc. (US).

Benefits for biomarkers market stakeholders

The report provides revenue estimates for the overall market and its subsegments, enabling stakeholders to assess commercial opportunities and competitive dynamics. Its product innovation, market development, diversification and competitive assessment coverage supports strategic planning across biomarker discovery, assay development, clinical validation, diagnostics and personalized medicine.

Key Attributes:

Key Topics Covered:

Market Dynamics

Drivers

Challenges

Case Studies Industry Trends Opportunities

Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/h17yko

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.